bluuebunny/crossref_metadata_2025_split huggingface dataset:
HYPERTENSION EXAGGERATES LEFT VENTRICULAR HYPERTROPHY IN FABRY PATIENTS
Authors: Gambardella Jessica , Spinelli Letizia , Fiordelisi Antonella , Aria Massimo , Cerasuolo Federica Andrea , Avvisato Roberta , Buonaiuto Antonietta , Borghi Claudio , Graziani Francesca , Muiesan Maria Lorenza , Biagini Elena , Pieroni Maurizio , Riccio Eleonora , Pisani Antonio , Virdis Agostino , Sorriento Daniela , Iaccarino Guido 
Published: May 2024

Objective:
Left ventricular hypertrophy (LVH) and dysfunction are the main causes of death in patients with Fabry Disease (FD). Identification of clinical predictors of FD evolution is crucially important for the correct timing of therapeutic intervention. On this ground, we aim to evaluate the impact of hypertension (H) as a predictor of (LVH) progression in FD.

Design and method:
We compared the FD database (319 patients) with patients from the URRAH study [>15000 patients] for H, indexed ventricular mass (LVMi) and calculated the odds ratio (OR) for LVH development. In a murine model of FD (tg-R301Q/KO mice) we chronically infused phenylephrine (PE,100 mg/Kg, 14-Days) by subcutaneous implantation of miniosmotic pump to increase blood pressure.

Results:
H in FD compared to URRAH exploded the LVH-OR by 6.3 times. In H patients, LVMi is significantly higher in FD than URRAH patients (FD, no H:98.8±47; FD, H:148.8±67.5 g/m2 p<0.01; URRAH, no H:103.6±29.6; U, H:112.4±31.3 g/m2, p<0.01). The multivariate analysis for sex and age indicated that FD and hypertension interact as independent risk factors for LVH. PE-exposure induced a comparable increase in systolic and diastolic blood pressure in FD and control mice. However, in FD mice PE induced a larger increase of LVMi, alongside with higher Heart-body weight ratio, and higher ANP and MEF2 cardiac levels. In FD heart, PE caused energetic stress signaling activation suggesting the potential involvement of AMPK-FOX03-axis in the hypertrophic response of FD-heart under hemodynamic stress.

Conclusions:
Our data suggest that H is associated with a higher risk of LVH, representing a clinical predictor of a worsened evolution of FD cardiac phenotype. Data from the murine model confirm the exaggerated hypertrophic response to H of FD heart, probably due to energetic stress induced by the increased cardiac workload.
FEATURES OF ANTIHYPERTENSIVE THERAPY IN YOUNG KAZAKH PATIENTS WITH ARTERIAL HYPERTENSION
Authors: Mukhtarkhanova Dilayra , Junusbekova Gulnara , Tundybayeva Meiramgul , Baglanova Lyazat , Samitova Sabina , Chingis Medet , Torzhan Ulbolsyn 
Published: May 2024

Objective:
Hypertension is the one of the most common diseases and one of the most prevalent causes of mortality and disability. Due to higher cardiovascular risk in patients with hypertension they need to achieve control BP to prevent cardiovascular events: myocardial infarction, stroke, heart failure. The main aim of the study is to assess the features of antihypertensive therapy and achievement of control of blood pressure in young non-organized population of Republic of Kazakhstan.

Design and method:
Prospective cross-sectional studies were conducted in 2021 in Kazakhstan, included 1110 young adults of both sexes (670 women (60%) and 440 men (40%)) of mean age - 31±8 years (95% CI 31-32). Special survey, including cardiovascular risk factors assessment, blood pressure and heart rate measurement were performed. The features of therapy were assessed: proportion of those on therapy, proportion of those adherent to therapy and proportion of those with controlled blood pressure. Statistical test was performed by the StatTech, Russia.

Results:
Percentage of those on antihypertensive medications – 20% of all hypertensive participants (50% of those who know about their high blood pressure). 45% of those on therapy are adherent to antihypertensive medications. Percentage of those proportion who take medications only when necessary – 25%. 14% of participants forget to take medication. In 49% of cases (of those on antihypertensive therapy) blood pressure levels were controlled.

Conclusions:
Only 50% participants of those who knows about their increased blood pressure take antihypertensive medications. Quarter of them take medications only by necessity. According to our data only half of participants on antihypertensive therapy have controlled arterial hypertension. It is important that young patients require more careful management.
HYPERTENSION TREATMENT IN LOW-INCOME COUNTRIES BY POSTTRANSLATIONAL MODIFICATION OF ANGIOTENSIN II
Authors: Lellig Michaela , Muñoz-castañeda Juan , Hermann Juliane , Noels Heidi , Rodríguez Mariano , Tepel Martin , Jankowski Joachim , Jankowski Vera 
Published: May 2024

Objective:
Although hypertension is a worldwide health problem, treatment options in low-income countries are still limited, resulting in high mortality. Therefore, the availability of drugs that are affordable and accessible to patients in low-income countries is still an urgent need. Since angiotensin II is one of the essential vasoconstrictive peptides in the human organism, we analyzed the impact of its posttranslational modification to pyruvamide-Ang II by pyridoxal-5’-phosphate on blood pressure. Pyridoxal-5’-phosphate is a less expensive vitamin B6 derivative and therefore could be a novel, cost-effective drug for the treatment of hypertension.

Design and method:
The post-translational modification of angiotensin II to pyruvamide-angiotensin II by pyridoxal-5’-phosphate was investigated in vitro by mass spectrometry. Calcium ion influx into vascular smooth muscle cells treated with angiotensin II or pyruvamide-angiotensin II, respectively, was also investigated in vitro. In ex vivo experiments, the vasoconstrictive effect of angiotensin II and pyruvamide-angiotensin II, respectively, was analyzed by using the bioassay of the isolated perfused rat kidneys. Furthermore, angiotensin II and pyruvamide-angiotensin II were investigated in in vivo experiments. Both Wistar Kyoto rats and spontaneously hypertensive rats were treated with pyridoxal-5’-phosphate by using mini-osmotic pumps and the blood pressure was measured time-dependently.

Results:
Calcium ion influx in vascular smooth muscle cells after stimulation with pyruvamide-angiotensin II was significantly decreased compared to angiotensin II. Perfusion pressure of isolated perfused rat kidney increased less by pyruvamide-angiotensin II than by angiotensin II. The systolic and diastolic blood pressure of spontaneously hypertensive rats treated with pyridoxal-5’-phosphate decreased from 171/139 ± 5 mmHg to 129/98 ± 2 mmHg after three days. The blood pressure of Wistar Kyoto rats treated with angiotensin II increased to 167/133 ± 3 mmHg, while the blood pressure of Wistar Kyoto rats treated with angiotensin II and pyridoxal-5’-phosphate decreased to 129/99 ± 2 mmHg.

Conclusions:
Pyridoxal-5’-phosphate significantly decreased rat blood pressure and might be a cost-effective drug for hypertension treatment. Respectively, an increased pyridoxal-5’-phosphate intake recommendation in the form of vitamin B6 intake might have a decreasing effect on blood pressure in the hypertensive population.
ANTIHYPERTENSIVE DRUGS IN CHRONIC HEART FAILURE IN THE CZECH REPUBLIC, FOCUSING ON BETA-BLOCKERS
Authors: Labr Karel , Spinar Jindrich , Parenica Jiri , Spinarova Lenka , Malek Filip , Spinarova Monika , Krejci Jan , Jarkovsky Jiri , Benesova Klara , Labrova Ruzena , Ludka Ondrej 
Published: May 2024

Objective:
Hypertension is a very common comorbidity in patients with heart failure. Beta-blockers (BB) are the first choice drug together with angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) in patients with heart failure with reduced left ventricular ejection fraction (HFrEF), reducing morbidity and mortality.

Design and method:
Data were collected in the FARmacology and NeuroHumoral Activation Registry (FAR NHL). Patients with chronic heart failure with left ventricular ejection fraction (LVEF) < 50% for at least one month were included.

Results:
1,100 patients with a mean age of 65 years, 80.8% male, were included. The mean systolic blood pressure was 128.0 mm Hg, mean diastolic blood pressure was 80.0 mm Hg. Of all patients, 20% received low dose of beta-blocker (LD), 57% medium dose (MD) and 17% high dose (HD), 6.2% did not receive BB. The higher the blood pressure (LD 124/ 77; MD 129/ 80; HD 132/ 82 mm Hg; p < 0.001), LV EF (LD 29.5; MD 30.5; HD 32.0%; p = 0.003), creatinine clearance (LD 78.7; MD 87.8; HD 91.1 ml/min; p = 0.001) or weight of the patients, the higher the BB dose they received (LD 83.2; MD 88.7; HD 93.5 kg; p < 0.001). The lower the NT-proBNP, the higher the BB dose patients received (LD 767; MD 456; HD 314 pg/ml; p < 0.001). The presence of atrial fibrillation (AF) did not affect the BB dose. Patients with AF were more likely to be treated with digoxin or a combination of digoxin and BB than patients without AF (p < 0.001).

Conclusions:
According to FAR NHL registry, almost 94% of patients with HFrEF receive BB. A total of 17% of patients take the target dose of BB. If a patient has BB, he/she is treated with the recommended preparation in more than 99% of cases. The more severe the disease, as reflected by lower BP, creatinine clearance, LV EF, weight or higher NT-proBNP, the lower the dose of beta-blockers the patient receives and tolerates.
COST-EFFECTIVENESS OF SINGLE-PILL AND SEPARATE-PILL ADMINISTRATION OF ANTIHYPERTENSIVE TRIPLE-COMBINATION THERAPY: A POPULATION-BASED MICROSIMULATION STUDY
Authors: Morabito Gabriella , Rea Federico , Gregorio Caterina , Ieva Francesca , Barbati Giulia , Corrao Giovanni , Mancia Giuseppe 
Published: May 2024

Objective:
To evaluate the lifetime cost-effectiveness profile of the perindopril/amlodipine/indapamide single-pill combination (SPC) compared with the combination of an angiotensin-converting enzyme inhibitor, a calcium-channel blocker, and a diuretic as a SPC of two drugs plus the third drug separately from the Italian payer perspective.

Design and method:
A cost-effectiveness analysis was conducted employing multi-state semi-Markov modeling and microsimulation. Using the healthcare utilization database of the Lombardy Region (Italy), 30,172 and 65,817 patients aged >=40 years who initiated SPC and two-pill combination, respectively, between 2015 and 2018 were identified. The observation period extended from the date of the first drug prescription until death, emigration, or December 31, 2019. Disease and cost models were parametrized using the study cohort, and a lifetime microsimulation was applied to project costs and life expectancy for the compared strategies Probabilistic sensitivity analysis with 1,000 samples was performed to address parameter uncertainty.

Results:
Compared with the two-pill combination, the SPC increased life expectancy by 0.86 years (95% confidence interval [CI] 0.61–1.14), with a reduction in total cost of –€12 (95% CI –9,719 to 8,131), making it the dominant strategy (ICER of –14, 95% CI –€15,871 to €7,113). The cost reduction associated with the SPC was primarily driven by savings in hospitalization costs, amounting to €1,850 (95% CI 17 to 7,813) and €2,027 (95% CI 19 to 8,603) for patients treated with the SPC and two-pill combination, respectively. Conversely, drug costs were higher for the SPC (€3,848, 95% CI 574 to 10,640 vs. €3,710, 95% CI 263 to 11,955). This was the case for all strata of age, sex, and clinical status.

Conclusions:
The SPC was projected to increase survival and reduce costs compared with the two-pill combination. This is likely explained by an improvement in drug compliance. As three-drug SPC is currently prescribed to only a few patients, the widespread use of this strategy could result in benefits for both patients and the healthcare system.
FOLLOW-UP OF SURVIVAL PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION
Authors: Rekovets Oksana , Sirenko Yuriy , Torbas Olena , Primak Galina , Granich Volodymyr , Kushnir Svitlana 
Published: May 2024

Objective:
Resistant arterial hypertension (RAH) contributes to high mortality worldwide.
Aim of the study: to assess 7-year follow-up survival and development of a composite end point (CEP) in patients with RAH.

Design and method:
The analysis includes 50 patients with RAH who were discharged from hospital. After 7 years discharge from the hospital, the patients underwent office BP measurement. Adverse events or death were reported as the composite endpoint (CEP). The average age of patients as of 2016 was 57.89 ± 11.81 y.o. 16% had type 2 diabetes (n=8).

Results:
After 7 years, in 32% (n=16) developed CEP, and 10% (n=5) of them died. The BMI increased from 30.87 ± 6.30 to 33.80 ± 6.90 kg/m2 (p<0.05). 20% had smoke (n=10), but 8% (n=4) (quit smoking after developing CEP). After 7 years, 48.88% of patients (n=22) controlled office blood pressure below 140/90 mmHg and 51.11% did not (n=23). Among patients who reached the target office BP (130.73 ± 6.61/81.59 ± 4.13 mmHg), there was a decrease in the number of drugs from 3.76 ± 0.19 to 2.85 ± 0.14, p<0.05. 45% (n=10) from the group took fixed combinations. Among patients who did not reach target office BP (148.04 ± 7.49/92.17 ± 4.66 mmHg), there was also a decrease in the number of drugs from 3.52 ± 0.18 to 2.50 ± 0.13, p<0.05 – patients decision. After regression analysis the main factors that were associated with the occurrence of CEP in patients with RAH were: the presence of diabetes (β= 5,237, p= 0,032) smoking (β=4,326, p= 0,037), increased body weight (β =3,423, p=0,024), failure to achieve target blood pressure levels (β =4,152, p=0,041)

Conclusions:
Mortality among patients with RAH were 10% during 7 years. The total composite endpoint were 32%. Did not reach the target office BP in patients with RAH the factors for the development of combined end point was diabetes mellitus, smoking and weight gain.
AN EXPLORATORY STUDY OF SERUM PROTEOMICS COMPARING SUBJECTS WITH TREATMENT-RESISTANT HYPERTENSION TO CONTROLLED HYPERTENSION
Authors: Elsadig Mohamed , Hameed Mohammed Awais , Grammatopoulos Dimitris , Dasgupta Indranil , Gill Paramjit , Medvecky Matej 
Published: May 2024

Objective:
The mechanism of treatment-resistant hypertension (TRH) is not fully understood yet. However, studies suggest the involvement of vascular endothelial dysfunction and systemic inflammation as contributors to the pathogenesis. This study aims to identify any measurable differences in protein abundance between two groups of hypertensive adults, controlled hypertension (CH) and TRH, using proteomics analysis techniques.

Design and method:
The study samples were obtained from an existing observational cohort study involving CH and TRH groups; venous blood samples were previously stored at -80°C, and appropriate consenting and ethical approval was obtained. TRH was defined blood pressure (BP) of 140/90 mmHg or more, on 3 or more antihypertensive agents or controlled BP (less than140/90 mmHg) after taking 4 or more antihypertensive agents. The study was conducted in two phases: the discovery phase, where 60 samples of matched group's (CH, n=30, TRH n=30) Peripheral venous serum samples were initially depleted from the highly abundant proteins before undergoing trypsin digestion, this was followed by Liquid Chromatography Mass Spectrometry analysis. The validation phase included 140 candidates (CH n=81, TRH n=59). Results were statistically analysed using an independent T-test, P valve <0.05 was considered to be statistically significant. Gen Ontology (GO) description is used for the functional description of the proteins.

Results:
Full results analysis is still undergoing by the time this abstract is being submitted, however, 12 different proteins were found to be significantly different in their expression between the two groups: Alpha 1B glycoprotein, Leucine-rich alpha 2 glycoproteins, Inter alpha trypsin inhibitor heavy chain H3, Lumican, Complement component C9, Complement factor D, Contactin-1, Lysozyme C, Phospholipid transfer protein, and Vascular cell adhesion protein 1.Initial GO analysis suggests above proteins are involved in vascular integrity, endothelial function and inflammatory response.

Conclusions:
There are significant differences in the proteins expression between patients with TRH and CH. This may allow better understanding of TRH, and treatment strategies.
SOCIAL DETERMINANTS OF HEALTH, BLOOD PRESSURE CLASSIFICATION, AND INCIDENT STROKE IN COMMUNITY-DWELLING ADULTS: A PROSPECTIVE COHORT STUDY
Authors: Chen Chaolei , Feng Yingqing 
Published: May 2024

Objective:
To determine whether the association of blood pressure (BP) categories, defined by the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) BP guideline, with stroke differ among Chinese adults with low or high burden of unfavorable social determinants of health (SDOH).

Design and method:
Analyses were conducted in the prospective sub-cohort of the China Patient-Centered Evaluative Assessment of Cardiac Events Million Persons Project, started in 1, July 2017 and followed stroke events until 31, June 2023. Participants were divided into groups with low and high burden of unfavorable SDOH, which consisted of educational attainment, economic stability, health care access, social support, and neighborhood relationship. Within each group, participants were categorized as having normal BP (systolic BP [SBP] <120 mm Hg and diastolic BP [DBP] <80 mm Hg), elevated BP (SBP 120-129 mm Hg and DBP <80 mm Hg), stage 1 hypertension (SBP 130-139 mm Hg or DBP 80-89 mm Hg), and stage 2 hypertension (SBP no less than 140 mm Hg or DBP no less than 90 mm Hg). The association between BP categories and stroke were examined within each SDOH group, separately, using multivariable-adjusted Cox proportional hazards models.

Results:
Of the 96,686 adults included in this study (mean [SD] age, 53.8 [10.1] years; 59,080 [61.1%] women), 64,823 (67.0%) were categorized as having high burden of unfavorable SDOH. Over a median follow-up of 5.0 years, 4,673 (4.8%) new-onset stroke events occurred. In the group of low burden of SDOH, hazard ratios (95% CI) for stroke for elevated BP, stage 1 hypertension, and stage 2 hypertension vs normal BP were 1.09 (0.86-1.37), 1.14 (0.94-1.37), and 1.59 (1.33-1.90), respectively. In the group of high burden of SDOH, hazard ratios for stroke events for elevated BP, stage 1 hypertension, and stage 2 hypertension vs normal BP were 1.20 (1.04-1.38), 1.45 (1.29-1.62), and 1.71 (1.53-1.91), respectively. Results were similar after excluding those taking antihypertensive medications.

Conclusions:
Lower BP categories were closely associated with increased risk of stroke in the context of high burden of SDOH. Early counseling and surveillance of high BP should be emphasized within socioeconomically disadvantaged populations.
ASSOCIATION OF SEVERE SLEEP APNOEA IN PRIMARY ALDOSTERONISM
Authors: Tanaka Yasushi 
Published: May 2024

Objective:
It is well known that sleep apnoea and primary aldosteronism are related. However, it is unclear whether aldosterone excess contributes to the severity of sleep apnoea. We investigated factors correlated with sleep apnoea in patients with primary aldosteronism: the endocrine system, including aldosterone, cardiac function, renal function, and blood pressure.

Design and method:
We performed a 3% oxygen saturation index with a pulse oximeter in 50 patients (54% male, 49 ± 7.3 years) diagnosed with primary aldosteronism scheduled for adrenal vein sampling in 2017-2020. 3% oxygen saturation index results were classified as mild (less than 5), moderate (5-15), or severe(15 and above) sleep apnoea. In addition, we compared aldosterone (radioimmunoassay), renin activity, aldosterone/renin activity, brain natriuretic peptide, estimated glomerular filtration rate and blood pressure at the initial visit in the severe group and other groups.

Results:
The severe group did not have higher aldosterone than the mild (192.7 ± 114.7 vs 238.9 ± 128.8 pg/mL, P=0.640) and moderate (192.7 ± 114.7 vs 187.5 ± 85.5 pg/mL, P=0.995) groups, and the same results were obtained for renin activity and aldosterone/renin activity. In other parameters, estimated glomerular filtration rate was not significantly different between groups, but systolic blood pressure at the initial visit in the severe group was significantly higher than in the mild (175.3±25.7 vs 144.8±18.7 mmHg, P=0.003) and moderate (175.3±25.7 vs 143.0±18.5 mmHg, P=0.003) groups. Similarly, brain natriuretic peptide in the severe group was significantly higher than in the mild (53.5±90.0 vs 12.7±8.3 pg/mL, P=0.020) and moderate (53.5±90.0 vs 10.7±11.2, P=0.014) groups.

Conclusions:
Our results showed that aldosterone excess did not contribute to the severity of sleep apnoea. However, severe sleep apnoea was significantly associated with elevated systolic blood pressure and brain natriuretic peptide.
HYPERTENSION AND VASCULAR RIGIDITY MEASUREMENTS IN ABORIGINAL AND NON-ABORIGINE POPULATIONS OF NORTHERN ARGENTINE DURING 2023
Authors: Romano José René , Olga Yegros , Anair Fernandez 
Published: May 2024

Objective:
Valuate central aortic pressure and blood pressure in 2 populations in the city of formosa in the year 2023, differences between them, degree of control. It has that one of such populations has its own socio-cultural characteristics.a prospective observational type study was carried out

Design and method:
taking the central blood and aortic pressure with standardized measurements with a tel or graph tensiometer, The data was taken during 3 months of 2023 in 2 institutions one a primary care center in an aboriginal(a) neighborhood of the toba race and another in the central hospital, both public institutions, have a prior diagnosis of hta. the data was analyzed in the statistix 7.0

Results:
study 75 patients, 30 a and 45 non-aborigine (na), the age was 56 in na and 50 in a, the sex of the patients was 25% men (m) in na and 53% h in a. the systolic pressure was 1/2 of 146 in no a and 117 in a, the diastolic pressure 89 in na and 67 in a, the pwv 9.2 in na and 7.3 in a, the increase index 29 in na and 15 in a.

Conclusions:
found in similar populations, lower values of vop, ta and increase index in the aboriginal population studyed. we should study more population to see if the data are correct and then see the cause
INFLUENCE OF STATINS ON ARTERIAL STIFFNESS AND BLOOD PRESSURE CONTROL IN PATIENTS WITH SEVERE ARTERIAL HYPERTENSION
Authors: Radchenko Ganna , Sirenko Yuriy 
Published: May 2024

Objective:
In some studies, there was well established a statin influence on arterial stiffness. It was suggested statins could decrease the blood pressure too. Pulse wave velocity (PWV), a gold standard for arterial stiffness measurement, depends on blood pressure (BP). The aim of study was to evaluate the influence of statins on PWV changes in dependency on normalization of the 24-h BP.

Design and method:
In study, there were included 46 patients (mean age 55.6 ±1.07, f/male 47.8/52.2%) with systolic (SBP)/diastolic (DBP) BP >/=180/110 mmHg, who were treated in specialized unit. Baseline and at the 6th month of combination therapy (mean medicines - 3.8±1.2), we provided office/ambulatory BP and PWV measurements.

Results:
At 6th month, only 39.1% had 24-h BP <130/80. PWV changes under treatment are present in tab. In statin treatment group we noted significant PWV lowering in spite of BP control. In patients without statins, PWV decreased significantly only in subgroup with achieved the target 24-h BP. In statin group 66.7% achieved target 24-h BP compared to 33.3% in statin (-) group (p=0.048).

Conclusions:
The statin therapy is able to improve the arterial stiffness (independently to BP control) and helps to achieve the target BP.